A neural network-based method for polypharmacy side effects prediction

Background Polypharmacy is a type of treatment that involves the concurrent use of multiple medications. Drugs may interact when they are used simultaneously. So, understanding and mitigating polypharmacy side effects are critical for patient safety and health. Since the known polypharmacy side effects are rare and they are not detected in clinical trials, computational methods are developed to model polypharmacy side effects. Results We propose a neural network-based method for polypharmacy side effects prediction (NNPS) by using novel feature vectors based on mono side effects, and drug–protein interaction information. The proposed method is fast and efficient which allows the investigation of large numbers of polypharmacy side effects. Our novelty is defining new feature vectors for drugs and combining them with a neural network architecture to apply for the context of polypharmacy side effects prediction. We compare NNPS on a benchmark dataset to predict 964 polypharmacy side effects against 5 well-established methods and show that NNPS achieves better results than the results of all 5 methods in terms of accuracy, complexity, and running time speed. NNPS outperforms about 9.2% in Area Under the Receiver-Operating Characteristic, 12.8% in Area Under the Precision–Recall Curve, 8.6% in F-score, 10.3% in Accuracy, and 18.7% in Matthews Correlation Coefficient with 5-fold cross-validation against the best algorithm among other well-established methods (Decagon method). Also, the running time of the Decagon method which is 15 days for one fold of cross-validation is reduced to 8 h by the NNPS method. Conclusions The performance of NNPS is benchmarked against 5 well-known methods, Decagon, Concatenated drug features, Deep Walk, DEDICOM, and RESCAL, for 964 polypharmacy side effects. We adopt the 5-fold cross-validation for 50 iterations and use the average of the results to assess the performance of the NNPS method. The evaluation of the NNPS against five well-known methods, in terms of accuracy, complexity, and running time speed shows the performance of the presented method for an essential and challenging problem in pharmacology. Datasets and code for NNPS algorithm are freely accessible at https://github.com/raziyehmasumshah/NNPS .

[1]  H. Knothe,et al.  Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene , 1968 .

[2]  Russ B. Altman,et al.  Discovery and Explanation of Drug-Drug Interactions via Text Mining , 2011, Pacific Symposium on Biocomputing.

[3]  A. Majeed,et al.  Current and future perspectives on the management of polypharmacy , 2017, BMC Family Practice.

[4]  Tariq M. Alhawassi,et al.  Adverse Drug Events and Medication Errors in African Hospitals: A Systematic Review , 2017, Drugs - Real World Outcomes.

[5]  S. Conroy,et al.  Medication errors in the Middle East countries: A systematic review of the literature , 2012, European Journal of Clinical Pharmacology.

[6]  Hyeon-Eui Kim,et al.  Deep mining heterogeneous networks of biomedical linked data to predict novel drug‐target associations , 2017, Bioinform..

[7]  Carol Friedman,et al.  Drug-drug interaction through molecular structure similarity analysis , 2012, J. Am. Medical Informatics Assoc..

[8]  B. Franklin,et al.  Investigating the prevalence and causes of prescribing errors in general practice : the PRACtICe Study , 2012 .

[9]  Marinka Zitnik,et al.  Data Fusion by Matrix Factorization , 2013, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[10]  Léon Bottou,et al.  Stochastic Gradient Descent Tricks , 2012, Neural Networks: Tricks of the Trade.

[11]  A. Barabasi,et al.  Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.

[12]  R. Hubbard,et al.  Medication prescribing in frail older people , 2013, European Journal of Clinical Pharmacology.

[13]  Huamin Zhang,et al.  Synergy evaluation by a pathway-pathway interaction network: a new way to predict drug combination. , 2016, Molecular bioSystems.

[14]  Lei Huang,et al.  DrugComboRanker: drug combination discovery based on target network analysis , 2014, Bioinform..

[15]  Feng Liu,et al.  Predicting potential drug-drug interactions by integrating chemical, biological, phenotypic and network data , 2017, BMC Bioinformatics.

[16]  George Hripcsak,et al.  Detection of drug‐drug interactions through data mining studies using clinical sources, scientific literature and social media , 2018, Briefings Bioinform..

[17]  J. Manson,et al.  Salpingo-Oophorectomy at the Time of Benign Hysterectomy: A Systematic Review. , 2017, Obstetrics and gynecology.

[18]  C. Cirstoiu,et al.  Statistically based survival rate estimation in patients with soft tissue tumors , 2018, Romanian Journal of Orthopaedic Surgery and Traumatology.

[19]  F. Hajibabaee,et al.  Reviewing polypharmacy in elderly , 2017 .

[20]  Steven Skiena,et al.  DeepWalk: online learning of social representations , 2014, KDD.

[21]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[22]  Jaques Reifman,et al.  Data-driven prediction of adverse drug reactions induced by drug-drug interactions , 2017, BMC Pharmacology and Toxicology.

[23]  Yoshua Bengio,et al.  Understanding the difficulty of training deep feedforward neural networks , 2010, AISTATS.

[24]  M. O’Mahony,et al.  Adverse drug reactions in special populations - the elderly. , 2015, British journal of clinical pharmacology.

[25]  Zhiwei Cao,et al.  Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer , 2015, Nature Communications.

[26]  Xiangxiang Zeng,et al.  KGNN: Knowledge Graph Neural Network for Drug-Drug Interaction Prediction , 2020, IJCAI.

[27]  Nikos D. Sidiropoulos,et al.  Tensors for Data Mining and Data Fusion , 2016, ACM Trans. Intell. Syst. Technol..

[28]  Patient-Related Risk Factors for Self-Reported Medication Errors in Hospital and Community Settings in 8 Countries , 2012, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[29]  Reza Safdari,et al.  Computational prediction of drug-drug interactions based on drugs functional similarities , 2017, J. Biomed. Informatics.

[30]  Statistically Based Survival Rate Estimation in Patients with Soft Tissue Tumors , 2018 .

[31]  Ali Kashif Bashir,et al.  Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) , 2013, ICIRA 2013.

[32]  Hans-Peter Kriegel,et al.  A Three-Way Model for Collective Learning on Multi-Relational Data , 2011, ICML.

[33]  Emily R Hajjar,et al.  Polypharmacy, adverse drug reactions, and geriatric syndromes. , 2012, Clinics in geriatric medicine.

[34]  C. Oliveira,et al.  Interacciones medicamentosas y reacciones adversas a los medicamentos en polifarmacia en adultos mayores: una revisión integradora , 2016 .

[35]  U. Wieshmann,et al.  Self reported adverse effects of mono and polytherapy for epilepsy , 2012, Seizure.

[36]  Marlien Herselman,et al.  Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) , 2015 .

[37]  Bridget E. Begg,et al.  A Proteome-Scale Map of the Human Interactome Network , 2014, Cell.

[38]  Peer Bork,et al.  The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..

[39]  R. Sharan,et al.  INDI: a computational framework for inferring drug interactions and their associated recommendations , 2012, Molecular systems biology.

[40]  M. Brodie,et al.  Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. , 2012, Current opinion in neurology.

[41]  E. S. Louis Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. , 2009 .

[42]  Lior Rokach,et al.  Detecting drug-drug interactions using artificial neural networks and classic graph similarity measures , 2019, PloS one.

[43]  Jacques Ferlay,et al.  Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis , 2019, The Lancet. Global health.

[44]  E. Balk,et al.  Salpingo-oophorectomy at the Time of Benign Hysterectomy: A Systematic Review , 2016, Obstetrics and gynecology.

[45]  Rajarshi Guha,et al.  Synergy Maps: exploring compound combinations using network-based visualization , 2015, Journal of Cheminformatics.

[46]  Jianying Hu,et al.  Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects , 2015, Scientific Reports.

[47]  J. Feldman,et al.  Dangers of Polypharmacy , 2017 .

[48]  A. Januszewicz,et al.  Malignant hypertension: new aspects of an old clinical entity. , 2015, Polskie Archiwum Medycyny Wewnetrznej.

[49]  Yanli Wang,et al.  Predicting drug–drug interactions through drug structural similarities and interaction networks incorporating pharmacokinetics and pharmacodynamics knowledge , 2017, Journal of Cheminformatics.

[50]  Yi-Chun Chiang,et al.  The effect of medication therapy management service combined with a national PharmaCloud system for polypharmacy patients , 2016, Comput. Methods Programs Biomed..

[51]  S. Hernández-Díaz,et al.  Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. , 2011, Archives of neurology.

[52]  Wei Li,et al.  Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles , 2017, Artif. Intell. Medicine.

[53]  Zhiyong Lu,et al.  A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..

[54]  Gillian E. Caughey,et al.  What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.

[55]  Jure Leskovec,et al.  Modeling polypharmacy side effects with graph convolutional networks , 2018, bioRxiv.

[56]  A. Verrotti,et al.  The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection , 2019, Expert review of neurotherapeutics.